Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 16/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631463 | 0.94 | NR1H2 (0.55) | NR1H2NR1H3RXRA | |
| SCHEMBL3511764 | 0.92 | NR1H2 (0.62) | NR1H2NR1H3 | |
| SCHEMBL3509019 | 0.88 | NR1H2 (0.60) | NR1H2NR1H3RXRA | |
| SCHEMBL3505942 | 0.88 | NR1H2 (0.64) | NR1H2NR1H3RXRA | |
| SCHEMBL3509369 | 0.86 | NR1H2 (0.58) | NR1H2NR1H3RXRA | |
| SCHEMBL3507737 | 0.85 | NR1H2 (0.64) | NR1H2NR1H3RXRA | |
| SCHEMBL3507401 | 0.85 | NR1H2 (0.61) | NR1H2NR1H3RXRA | |
| SCHEMBL3507120 | 0.84 | NR1H2 (0.62) | NR1H2NR1H3RXRA | |
| SCHEMBL3505275 | 0.84 | NR1H2 (0.55) | NR1H2NR1H3RXRA | |
| SCHEMBL3507565 | 0.82 | NR1H2 (0.68) | NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | claimed |
| CN-101679311-A | Quinazoline compound | WYETH CORP | 2010-03-24 | — | — | CN | claimed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | claimed |
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| CN-101679311-A | Quinazoline compound | WYETH CORP | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | NR1H2 2/4885NR1H3 1/4885RXRA 11/4885 |
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | NR1H2 2/4885NR1H3 1/4885RXRA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.